Roche's Herceptin defenses breached as Kadcyla fails in MARIANNE
This article was originally published in Scrip
Executive Summary
Roche's novel anticancer Kadcyla has received a blow, failing the Phase III MARIANNE study that was designed to expand the use of the antibody-drug conjugate to the first-line setting in HER-2 positive advanced breast cancer.